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1. Summary 
   Chronic inflammation and/or autoimmune responses have been associated with a number of 
diseases including atherosclerosis, scleroderma, Sjogren’s syndrome, systemic lupus 
erythematosus (SLE) and others. Toll-like receptors (TLRs) are important receptors that 
recognize both exogenous and endogenous ligands and initiate signaling cascades, involving 
numerous adaptors, kinases and transcription factors, which ultimately lead to enhanced gene 
expression of cytokines and other factors associated with chronic inflammation or autoimmune 
reactions.  TLRs represent a family of membrane bound receptors that are part of the larger 
pattern recognition receptor (PRR) family.  TLRs play a role in both innate and adaptive 
immunity.  As such TLRs are central to the processes of chronic inflammation and 
autoimmunity.  In this review I discuss the molecular aspects of TLR signalling and how TLRs 
are involved in the pathogenesis of atherosclerosis and autoimmune diseases. 
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2. Introduction 
   Normal cellular physiology involves a complex network of molecular processes that involve 
signaling pathways and nuclear responses that maintain cellular homeostasis, respond to 
external stimuli and generally maintain overall equilibrium of the body state. Disease states are 
ultimately a reflection of dysfunctional or aberrant cellular physiology.  The immune system is 
one of the most complex biological systems in the body.  The immune system comprises two 
separate yet interconnected systems, 1) the innate immune response and 2) the adaptive immune 
response. 
The innate immune response is found in nearly all forms of life including both plants and 
animals (Litman GW, 2005), however the adaptive immune response is specific to vertebrates 
(Mayer, 2006).  The two types of immunity serve to protect the body from external threats such 
as microbial infection, viral infection and various other pathogens.  The innate immune 
response provides an immediate but non-specific defense against infection, while the adaptive 
immune response leads to pathogen and antigen specific responses.  If an infection is 
unsuccessfully eliminated by the innate immune response then the innate system can signal to 
the adaptive immune response as a subsequent line of defense. An important difference between 
the two systems is that the adaptive response has immunological memory, that is, it can mount 
a faster and stronger response upon subsequent infection to an antigen that has previously been 
encountered.  Additionally, the adaptive immune response is antigen specific and is able to 
distinguish between self and non-self antigens.  Adaptive immunity is mediated by multiple cell 
types including T-cells, B-cells, NK cells and gamma delta T cells. There are multiple disorders 
associated with dysfunctional or aberrantly functional immune systems including 
immunodeficient diseases, autoimmunity and cancer.  
    
2 
Cardiovascular diseases such as coronary heart disease and stroke are the number one cause of 
death worldwide (World Health Organization, 2012). Atherosclerosis is a complex 
inflammatory disease and is the main driver of coronary artery and cerebrovascular disease.  
Atherosclerosis is now known to be a disease associated with chronic inflammation driven by 
the innate immune system Monocytes and macrophages, cellular components of innate 
immunity, play a major role in atherosclerosis (Seneviratne, Sivagurunathan, & Monaco, 2011).   
Autoimmune diseases include a wide range of diseases in which the adaptive immune system 
recognizes self-antigens and attacks normal cells and tissues.  About 78% of autoimmune 
diseases affect women and the underlying reason for this gender specificity is unclear (DeLisa 
Fairweather, 2008) .  Diseases with this underlying mechanism include systemic lupus 
erythromatosus (SLE), type I diabetes, scleroderma, and Sjogren’s syndrome among others.  In 
the case of SLE for example, patients present with a variety of symptoms as the disease can 
affect multiple targets including skin, joints, kidneys lungs, CNS, vascular systems and other 
organs.  Severe renal disease and accelerated atherosclerosis are the main drivers of morbidity 
and mortality in SLE. 
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3. Innate Immunity 
   The innate immune system is considered the primary mechanism of defense against infections 
(Parham, 2009) .The innate immune system is responsible for the recognition of the existence 
and type of infection, as well as the regulation and choice of effector mechanisms in the adaptive 
immune response (Medzhitov R. , 2001).  The response of innate immunity is mediated by 
different cells, including phagocytes, macrophages, dendritic cells (DCs) and antigen 
presenting cells (Mogensen T. H., 2009).  In order to maintain homeostasis, the innate immune 
system will supervise/inspect for any exogenous pathogens or destruction through their pattern 
recognition receptors (PRR) (Frantz, Ertl, & Bauersachs, 2007)  
 
Figure 1. Detection of pathogen-specific molecules by the PRRs. Once pathogen specific 
molecules are detected and recognized, an immune response will be activated. The end result 
is either resolution of the infection or progression to inflammatory disease/autoimmunity 
(Mogensen T. H., 2009) 
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4. Pattern Recognition Receptors 
   Pathogen components; lipopolysaccharide (LPS), endotoxins, glycans are some of the 
archetypal pathogen associated molecular patterns (PAMPs) that are recognized by the pattern 
recognition receptors (PRRs). PRRs are located both on the cell surface and in the cytoplasm 
where they detect PAMPs, such as lipopolysaccharide (LPS), released from Gram-negative 
bacteria or viral RNA (Newton & Dixit, 2012).  PRRs are expressed on a variety of cell types 
including among others macrophages, dendritic cells and B cells and are independent of 
immunological memory (Shoenfeld, 2004).  Each specific type of PRR reacts with a unique 
PAMP, displays a specific expression pattern, activates a specific signaling pathway and results 
in an unequivocal anti-pathogen response (Akira, Uemtasu, & Takeuchi, 2006) Once these 
PAMPs are recognized, PRRs signalize to the host the presence of infection and provoke an 
antimicrobial response by way of activating a number of intracellular signaling pathways, 
involving a variety of adaptor molecules, kinases and transcription factors (Akira & Takeda, 
Toll-like receptor signalling, 2004).  PRR-induced signal transduction pathways  result in the 
activation of gene transcription and synthesis of immune response molecules, including 
cytokines, chemokines, cell adhesion molecules, and immunoreceptors (Akira, Uemtasu, & 
Takeuchi, 2006). Together they form an early reposnse to infection along with forming a link 
to the adaptive immune response. There are two broad groups of PRRs; cytosolic receptors 
consisting of RIG-I-like receptors (RLRs) and NOD-like receptors (NLRs); as well as 
transmembrane receptors that are the C-type lectin receptors (CLRs) and Toll-like receptors 
(TLRs) (Takeuchi O, 2010).   
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5. Toll-Like Receptors 
   TLRs are a family of receptors and each receptor is functionally specific for a different set of 
microbial products. TLRs are expressed on different cell types, such as macrophages, mast 
cells, B cell, and dendritic cells among others.  Toll receptors were first identified as important 
for innate immunity in the fruit fly Drosophila (Takeda, Kaisho, & Akira, 2003).  TLRs are the 
most extensively studied of the receptors belonging to the PRR class. TLRs belong to the type 
1 transmembrane protein class comprised of a transmembrane domain that determines cellular 
localisation, and an intracellular toll-interleukin 1 receptor (TIR) domain essential for 
downstream signalling (Seneviratne, Sivagurunathan, & Monaco, 2011)  The TLRs exhibit a 
trimodular structure (Kumar, Kawai, & Akira, 2009)  consisting of an extracellular N-terminal 
domain and a intra-cellular C-terminal region; The N-terminal is made of roughly 16-28 leucine 
rich repeats (LRRs) and it recognizes PAMPs (Kumar, Kawai, & Akira, 2009), while the C-
terminal domain, also called Toll/IL-1 receptor (TIR) is analogous to the cytoplasmic region of 
IL-1R (Janeway Jr & Medzhitov, 2002., Akira, Uemtasu, & Takeuchi, 2006., Medzhitov R. , 
2007., Beutler, 2009).  Out of the 13 known TLRs, 10 have been identified in humans and 13 
in mice (Akira, Uemtasu, & Takeuchi, 2006).  Each TLR can respond to either exogenous 
ligands and potentially endogneous ligands to elicit a downstream signalling cascade as outlined 
in Table 1. 
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Table 1. Human and mouse TLRs with their respective endogenous and exogenous        ligands. 
(Mingcai Li, 2009) 
 
A division can be made based on the location of the TLRs; one group are the cell membrane 
TLRs (TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11) while the other group, which are 
nucleic-acid sensing; (TLR3, TLR7, TLR8 and TLR 13), are located in intracellular vesicles 
such as the endoplasmic reticulum lysosomes and endosomes (Cole, Mitra, & Monaco, 2010) 
(Kawai & Akira, 2010).  The subfamilies of TLRs are related to the PAMPs they recognize; 
lipids are recognized by the subfamily comprised of TLR1, TLR2 and TLR6, while nucleic 
acids are recognized by the group of TLR7, TLR8 and TLR9.  TLR gene expression is 
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influenced by pathogen response, a vast array of cytokines and  environemntal stressors (Akira, 
Uemtasu, & Takeuchi, 2006).   
6. TLR 2, 4, 7, 8, 9 
   TLR 2 and 4 are located on the cell surface and recognize a large number of ligands; TLR-2 
is involved in peptidoglycan and lipoarabinomannan recognition as TLR2- deficient mice are 
unable to recognize these molecules (Takeuchi, et al., 1999., Takeuchi, et al., 2000).  TLR-2 
ligand recognition also requires related TLR family members TLR-1 and TLR-6 (Toubi & 
Shoenfeld, 2004).  TLR4 was the first identified human TLR. TLR4 has been implicated in the 
recognition of viral proteins, which leads to the production of a wide range of cytokines and 
chemokines (Mogensen & Paludan, 2005., Shimazu, Akashi, Ogata, & a.l, 1999., Kurt-Jones, 
Popova, Kwinn, & al., 2000).  Multiple TLR4 ligands have been identified (Table 1) and some 
have been proposed to function as the ligand for TLR4 in the process of atherosclerosis (Den 
Dekker WK, 2010). One example of a TLR4 ligand is fibronectin, a high-molecular weight 
extracellular matrix glycoprotein. Immuno-stimulatory activities similar to those provoked by 
LPS have been described for the type III repeat extra domain A of fibronectin. TLR4 signaling 
is activated in response to its recognition of the extra domain A of fibronectin (Okamura, 
Watari, Jerud, Young, & Ishizaka, 2001).  Several studies have shown that TLR-2 and TLR-4 
can recognize a number of self-proteins, including members of the heat shock protein (HSP) 
family. For example, HSP60 and HSP70 which are normally intracellular proteins, can also 
function as  “danger” molecules when released under stress or following extensive apoptosis. 
These HSPs utilize the  TLR-2 and TLR-4 signaling pathways to activate vascular smooth 
muscle cells and macrophages which leads to secretion of pro-inflammatory cytokines such as 
TNF-a and IL-12, and over-expression of co-stimulatory molecules on APCs (Toubi & 
Shoenfeld, 2004).  The TLR9 subfamily including TLR7, TLR8 and TLR9 is located in the 
cytoplasmic compartments of the endoplasmic reticulum and endosome  and they are involved 
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in the discrimination of nucleic acid like structures in microorganisms (Hurst & von 
Landenberg, 2008).  TLR7 and/or TLR8 are able to recognize singlestranded (ss) guanosine 
and/or uridine rich RNA and ssRNA viruses.  In addition, both receptors can recognize synthetic 
antiviral nucleoside analogs such as imidazoquinolines or loxoribine (Hurst & von Landenberg, 
2008).  TLR7 and TLR8 are highly homologous to TLR9 and while putative natural ligands for 
TLR7 and TLR8 have been suggested but not definitively shown , it is known that they 
participate in the discrimination of nucleic acid-like structures in microorganisms (Takeda, 
Kaisho, & Akira, 2003).  
7. TLR-Dependent Signalling Cascades 
   Upon initial recognition of PAMPs by the TLR receptors a series of cascade events leads to 
upregulation of genes required for inflammation. Most members of the TLR family form homo-
dimers with the exception of TLR2 and TLR4 which form hetero-dimers with TLR1 and TLR6 
respectively (Seneviratne, Sivagurunathan, & Monaco, 2011).  TLR signalling is augmented by 
the recruitment of five different adaptor proteins to its TIR domain.  These adaptor proteins 
include TRIF (TIR domain containing adaptor inducing IFN-β), TIRAP/MAL (TIR domain 
containing adaptor protain/MyD88 adaptor like protein), TRAM (TRIF related adaptor 
molecule) and SARM (Steile-a and armadillo motif-containing protein) (Akira, Uemtasu, & 
Takeuchi, 2006). Different downstream signalling events are determined by whether the TLR 
interacts with MyD88 or TRIF.  Previous studies have demonstrated the importance of MyD88 
in the host defense against lipoproteins,  CpG DNA, peptidoglycans or imidazoquinolines. In 
mice lacking MyD88, macrophages failed to produce any inflammatory cytokines (Takeda, 
Kaisho, & Akira, 2003).  All TLRs, with the exception of TLR3, require MyD88 to initiate 
downstream signalling events. TLR2 and TLR4 signalling uses an adaptor molecule 
TIRAP/MAL as a bridge between the TLR and MyD88 (Fitzgerald et al.,2001; Horng et al., 
2001,2002; Yamamoto et al., 2002a).  Following ligand activation MyD88 recruits members of 
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the IL-1 receptor associated kinase (IRAK) family.  The IRAKs subsequently dissociate from 
MyD88 and associate with TRAF6 which is an E3 ubiquitin ligase (Xia, Sun, Chen, et al., 2009)  
Unconjugated polyubiquitin chains activate a molecular complex consisting of TAK1 and 
TAK1-binding proteins which then translocate to the cytoplasm.  In the cytoplasm TAK1 
phosphorylates IKK-β, which is part of a complex consisting of IKKα, IKKβ and NEMO.  This 
complex is then responsible for phosphorylation of IκBα, which is an inhibitor of the 
transcriptional regulator NF-kB.  Once phosphorylated IkBα releases NF-κB which then 
translocates to the nucleus and activates genes responsible for inflammation.  TAK1 
additionally phosphorylates MAPK6 which results in the downstream activation of the MAPKs 
Erk1, Erk2, p38 and JNK.  Activation of this pathway leads to activation of the transcription 
factor AP-1  which is involved in the control of many genes including those encoding cytokines 
(Seneviratne, Sivagurunathan, & Monaco, 2011).   
TLR3 uses the TRIF coactivator to activate a signalling cascade the ultimately leads to the 
activation of the transcription factors IRF3 and NFκB (Alexopoulou L, 2001). TRIF associates 
with TRAF3 and TRAF6.  TRAF3 activates TBK1 and IKKe which phosphorylate the 
cytoplasmic form of IRF3 which upon phosphorylation then translocates to the nucleus to 
activate gene expression (Oganesyan G, 2006., Hacker H, 2006).  IRF3 activates among others 
genes for the production of pro-inflammatory cytokines, type 1 interferons and subsequently 
IFN dependent genes.  NFκB activation results when a complex consisting of TRADD, FADD 
and RIP1 leads to TRADD dependent poly ubiquitination of RIP1.  In addition, TRIF interacts 
with TRAF6 to activate TAK1 in a ubiquitination dependent process which leads to IKKα 
phosphorylation and release of NFκB (Alexopoulou L, 2001). TLR4 is a special case in that it 
can utilize both the MyD88 and TRIF pathways in signaling activation.Which pathway is used 
is determined by the receptor's cellular localisation (Tanimura N, 2008., Kagan JC, 2008).  In 
one case, membrane bound TLR4 recruits MyD88 which binds to MAL leading ultimately to 
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activation of the transcriptional regulator NFkB.  In the second instance, TLR4 translocates to 
the endosome via dynamin mediated endocytosis. In the endosome, TLR4 associates with 
TRAM to activate the TRIF pathway resulting in IRF3 activation and at a later stage activation 
of NFkB and MAPK (Tanimura N, 2008., Kagan JC, 2008., Rowe DC, 2006)  
 
Figure 2. TLR signalling cascade showing MyD88 and TRIF dependant pathways (Akira, 
Uemtasu, & Takeuchi, Pathogen Recognition and Innate Immunity, 2006) 
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8. Atherosclerosis 
   Atherosclerosis is caused by many factors and is associated with risk for diseases such as 
coronary heart disease, cerebrovascular insults and peripheral vascular disease.  The problem 
of atherosclerosis is not just that it is a lipid-storing disease, but it is a chronic inflammatory 
process as well (Curtiss & Tobias, 2009).  Considering the fact that chronic inflammation is 
part of the etiology of atherosclerosis it has been noted that the innate immune response plays 
a crucial role in the progression of this disease and more specifically that certain TLRs play a 
role in either defending the host or advancing the disease (Seneviratne, Sivagurunathan, & 
Monaco, 2011., Den Dekker WK, 2010).  As a result of this chronic inflammation, the presence 
of cells such as macrophages, monocytes, leukocyte, dendritic cells and lymphocytes is 
observed in the area of atherosclerotic lesions and the damaged endothelial cells demonstrate 
an inflamed phenotype (Biragyn A, 2002).  One of the earliest lesions described in 
atheroslcerosis are fatty streaks.  These streaks are composed of foam cells and some smooth 
mucsle cells.  Lifestyle and genetic diseases influence the progression from fatty streaks to 
pathological lesions that can cause deleterious conseqeunces (Zieske A.W, 2002).   The most 
common risk factors associated with progression of atherosclerosis are diabetes mellitus, 
hypertension and hypercholesterolemias, as well as lifestyle habits such as smoking, high fat 
diet and sedentary lifestyle.    It is important to note that there is irregular distribution of 
atherosclerosis throughout the vascular bed which could be attributed to irregular  blood flow 
dynamics (Wasserman & Topper, 2004),  while regions of the arterial tree exposed to laminar 
flow are spared from endothelial activation and athersclerosis (Curtiss & Tobias, 2009).  Areas 
that are exposed to laminar  flow seem to be preserved from atherosclerosis and endothelial 
activation (Curtiss & Tobias, 2009).  Vessel bifurcations and the lesser curvature of the aortic 
arch are sites that present with an inflammed phenotype even in the absence of complicating 
disease states (Matharu N.M, 2006., Dai G, 2004., Feintuch A, 2007).  TLR expression has 
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been observed in endothelial cells that exhibit this proinflammatory phenotype suggesting a 
connection between TLR signaling and atherosclerosis (Curtiss & Tobias, 2009). 
9. TLRs and Atherosclerosis 
   The idea that TLRs participate in the process of atherosclerosis is becoming clear, although 
only two, TLR2 and TLR4, have been studied in any detail. Both endogenous and exogenous 
ligands promote disease by activation of TLR2 signalling, which is one route for both genetic 
and inflammatory pathways to atherosclerotic disease (Curtiss & Tobias, 2009).  Experiments 
with cultured human coronary artery endothelial cells exposed to conditions approximating 
disturbed flow conditions, similar to that found at sites of lesion development, showed up-
regulated responsiveness to TLR2 agonists (Dunzendorfer, 2004) due to enhanced expression 
of TLR2 in response to disturbed flow (Tobias P.S, 2007).  A number of studies utilizing TLR2 
deleted mouse models further substantiate the role of TLR2 in atherosclerosis.  Low-density 
lipoprotein receptor–deficient (Ldlr–/–) mice show increased susceptability for atherosclerosis 
and as such have been used for studies of TLR2 deficiecy TLR2 knockout in the Ldlr–/– 
background leads to complete deficiency of TLR2 and a reduction in atherosclerosis (Mullick 
A.E, 2005).  In the specific case where BM transplantation was used, loss of TLR2 expression 
from BM-derived cells had no effect on disease progression.  Furthermore, experiments have 
shown that, in the absence of a known exogenous agonist, loss of TLR2 expression on cells not 
of BM origin (such as endothelial cells) reduced atherosclerosis (Mullick A.E, 2005). Thus, it 
was postulated that an unknown endogenous TLR2 agonist influenced lesion progression by 
activating TLR2 in cells that were not of BM cell origin (Mullick A.E, 2005).  Early results 
with double knockout LDLr−/−TLR2−/− mice showed that total deficiency of TLR2 results in 
decreased lesion burden after 10 or 14 weeks of consuming a high-fat diet (Yamashita, 2006) 
Complete loss of this receptor resulted in decreased lesion size whereas systemic exposure to a 
TLR2 ligand dramatically increased lesion severity (Mullick A.E, 2005).  Thus, the existence 
13 
of a functional TLR2 promotes disease and suggests a clear role for TLR2 in modulating the 
severity of experimental atherosclerosis.  As TLRs have come to be recognized as potential 
therapeutic targets it is of note that  Arslan et al. reported the first humanized anti-TLR2 
antibody (OPN-305) which led to reduced infarct size, preserved systolic function and 
prevention of myocardial damage in a pig model of ischemia/reperfusion injury (Arslan, Keogh, 
McGuirk, & Parker, 2010., Arslan, et al., 2012). A second report showed that the DPP-4 (CD26) 
inhibitor alogliptin reduced atherosclerotic lesion size in diabetic mice and inhibited TLR4-
mediated pro-inflammatory cytokine expression in vitro (Ta, Schuyler, Li, Lopes-Virella, & 
Huang, 2011).  The TLR4 signaling pathway is mediated by the myeloid differentiation factor 
88 (MyD88) (as does TLR2) as well as the Toll/IL-1 receptor domain-related adaptor protein 
that induces interferon (TRIF).  Loss of MyD88 leads to reductions in plaque size, lipid content, 
expression of proinflammatory genes, cytokines, and the chemokines IL-12 and monocyte 
chemoattractant protein-1 (Michelsen K.S, 2004).  TLR4 has further been shown to  directly 
interfere with cholesterol metabolism in macrophages suggesting a mechanism by which TLR4 
may affect disease pathology (Castrillo A, 2003). A complete deficiency of TLR4 correlates 
with reductions in lesion size, lipid content, and macrophage infiltration in ApoE-/- 
(Apolipopreotein E) mice fed a high cholesterol diet for six months (Michelsen K.S, 2004).  
Notably, this reduction in disease severity in the absence of TLR does not seem to affect plasma 
cholesterol levels (Curtiss & Tobias, 2009). In at least one study ApoE−/− mice deficient in 
TLR4 exhibited a decreased development of atherosclerotic lesions (up to 55% less), and lower 
levels of monocyte infiltrated atherosclerotic lesions (with a 65% decrease) in 
ApoE−/−TLR4−/− compared to ApoE−/− mice (Michelsen K.S, 2004., Mullick A.E, 2005).  
Our current understanding of these processes suggests that blocking TLR2 and perhaps TLR4 
may reduce lesion formation and inflammation, while TLR2 blockade may also reduces infarct 
size (Falck-Hansen M, 2013).  Hyperlipidaemia and infectious disease are two prominent risk 
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factors that point to innate immune mechanisms as potential contributors to proatherogenic 
inflammation. The TLRs (Toll-like receptors) being pro-inflammatory sensors of pathogens, 
are therefore potential connection points between inflammation, infectious disease and 
atherosclerosis (Tobias P.S, 2007).  Michelsen et al. were the first to suggest a direct link 
between TLR4 and atherosclerosis formation (Michelsen K.S, 2004).  In this study 
TLR4/apolipoprotein E (ApoE) double knockout mice developed less atherosclerosis compared 
to ApoE knockout controls, although the intima reduction was less prominent as compared to 
MyD88/ApoE double knockout mice.  In both TLR4/ApoE and MyD88/ApoE double knockout 
mice this anti-atherogenic effect appeared to be independent of cholesterol levels (Den Dekker 
WK, 2010). In addition, a significant lower levels of lipids and macrophages in the plaque was 
observed in both TLR4/ApoE and MyD88/ApoE double knockout mice.  This suggests that 
TLR signaling may also be involved in advanced plaques and plaque vulnerability.  Michelsen 
et al. did not focus on progression into a vulnerable plaque, since ApoE−/− mice fail to develop, 
in the absence of additional maniuplation, plaques with a vulnerable phenotype (Den Dekker 
WK, 2010).   
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10. Autoimmune Diseases 
   Autoimmune diseases occur when the host's natural immunologic defenses start attacking 
healthy cells and tissue.  They can affect a variety of tissues and present with different 
symptoms based on the particular organ or cell type in question.  To date there is still no clear 
evidence about the exact pathogenesis of autoimmune disorders, but it is known that they are 
complex multifacteded disorders under the influence of genetics, environment and hormonal 
factors (Chen, Szodoray, & Zeher, 2015).  One major characteristic of autoimmune disorders 
is the existence of antibodies and T cells specific for antigens expressed by a targeted tissue; 
these antigens being called autoantigens, which are a subset of self antigens (Parham, 2009). 
Many of the commonly found autoantigens are release products of dead or dying cells.  Viral 
or bacterial infections are often associated with the onset and flare ups of systemic autoimmune 
disease (Banchereau J, 2004., C.J. & et al., 2005).  According to one model envisions a 
pathogenic process whereby dendritic cells and macrophages upon activation of their PRRs 
upregulate production of type I IFNs and cytokines .  Autoantigens presented to the immune 
system via APCs then activate potentially autoreactive T cells which subsequently activate and 
expand the population of auto-reactive B cells. These B cells undergo somatic hypermutation 
leading to expression and clonal expansion of pathogenic high affinity auto-antibodies.  These 
higher affinity autoreactive B cells are then targeted by auto-antigens that increase during the 
course of infection (Ronnblom L, 2001) .  Once self-tolerance is lost and there is a response 
from the adaptive immune system, an autoimmune disease can occur. In addition to microbial 
mechanisms of autoimmune induction, it is also possible that autoantigens not associated with 
infections can serve as endogenous PRR ligands and exert a proactive function in loss of 
tolerance (Marshak-Rothstein, 2006). 
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11. TLRs and Autoimmune Disease 
   In systemic autoimmune disorders such as SLE, scleroderma and Sjogren's syndrome a high 
proportion of autoantibodies associated with these diseases recognize DNA, RNA or 
macromolecular complexes that contain RNA or DNA (Marshak-Rothstein, 2006).  An 
increasing body of evidence suggests that these molecules are autoantigens because they have 
the ability to directly activate the innate immune system and thereby promote self-directed 
immune responses (Marshak-Rothstein, 2006).  Early clinical studies showed a correlation 
between aberrant expression of IFNa and SLE.  There are 13 subtypes of IFNα and they 
represent a pleiotropic cytokine family associated with immune responses to viral infection 
(Theofilopoulos, 2005).  
More direct evidence of the causal relationship between IFNα and SLE came from studies in 
which repeated administration of recombinant IFNα in patients with chronic viral infections or 
various cancers led to the production of antinuclear antibodies (ANA) and in some cases clinical 
presentation of symptoms associated with SLE or other autoimmune disorders (Ronnblom, et 
al.,1990., Gota & Calabrese, 2003).  IFNα contributes to disease pathogenesis either directly or 
indirectly via effects on antigen presenting cells (APC), T cells and B cells (Utz, Gensler, & 
Anderson, 2000). High amounts of IFNα are produced by a small but highly efficient type of 
cell known as the plasmacytoid dendritic cell (pDC) (Ronnblom & Alm, 2001).  The highly 
efficient response of pDCs to both microbial infection and SLE associated immune complexes 
is in large part due to the fact that pDCs constitutively express TLR7 and TLR9 (Kadowski, et 
al., 2001).  TLR7 was originally identified as a receptor for viral single-stranded RNA (ssRNA) 
(Diebold, Kaisho, Hemmi, Akira, & Reis e Sousa, 2004., Heil, et al., 2004., Lund, et al., 2004), 
while TLR9 was initially identified as a receptor that could distinguish between bacterial/viral 
DNA and mammalian host DNA (Krieg, et al.,1995., Hemmi & et al., 2000).  Unlike many 
other members of the TLR family that are membrane bound, TLR7 and TLR9 are found in the 
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cytoplasmic compartment, specifically the endoplasmic reticulum-endosome-lysosome array 
(Ahmad-Nejad & et al., 2002).  DNA-containing immune complexes activate cells through 
TLR9, while RNA-containing immune complexes activate cells through TLR7 (Marshak-
Rothstein, 2006).  Activation of pDCs by these complexes stimulates IFNα production and 
agents such as chloroquie or bafilomycin, which disrupt acidification of endosomes and block 
activation of TLR7 and TLR9,  lead to inhibition of IFNα production (Marshak-Rothstein, 
2006).  Activation of cytokine production is also inhibited by oligodeoxynucleotide (ODN) 
sequences that are known to block activation of TLR7 and TLR9 (Vollmer,et al., 2005., Barrat, 
et al.,2005., Lovgren, et al.,2006).  Furthermore, immune complexes consisting of purified 
snRNPs and monoclonal antibodies specific for the SmD subunit of snRNP can stimulate pDCs 
from wild type mice but not from TLR7 deficient mice (Savarese, et al., 2006).  Taken together 
these data suggest that nucleic acid-containing immune complexes activate TLR7- or TLR9 
containing pDCs and represent a key step in the pathogenic process leading to SLE. In addition 
to pDCs, B cells also express TLR7 and TLR9.  IFNα upregulates expression of both TLR7 and 
its associated adaptor MyD88 in human and mouse B cells and activates an increased response 
of B cells to TLR9 ligands (Marshak-Rothstein, 2006).  Because TLR7 and TLR9 are 
cytoplasmically located a question arises as to how they recognize exogenous ligands.  BCR 
mediated endocytosis is responsible for internalizing and presenting ligands intracellularly 
(Marshak-Rothstein, 2006).  Several studies using in vivo mouse models of SLE have begun to 
provide evidence consistent with the view that TLR7 and TLR9 play a central role in the 
production of pathogenic autoantiboes and the development of SLE (Marshak-Rothstein, 2006).   
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Table 2.  In vivo outcomes of aberrant TLR expression on mouse models with SLE (Marshak-
Rothstein, 2006).   
 
As a result of the likely involvement of TLR7 and TLR9 signalling in autoimmune disease, a 
number of studies have looked at the effect of TLR7 and TLR9 inhibitors on disease.  Two 
main classes of TLR7 and TLR9 inhibitors exist, one are the antimalarials and second are the 
inhibitory oligonucleotides (ODNs) (Lenert, 2006). Antimalarials have been the standard 
therapeutic for autoimmune disease over the last hundred years .  These compounds can inhibit 
the activation of both pDCs and B cells likely through inhibition of acidification and maturation 
of endosomes (Macfarlane & Manzel, 1998., Hacker, et al.,1998., Yi, et al., 1998).  Two classes 
of ODNs exist, the first contain CpG rich motifs and the second class consist of a repetitive 
element associated with mammalian telomeres (Barrat, et a., 2005., Lau, et al., 2005., Stacey, 
et al., 2003).  Inhibitory ODNs can antagonize both TLR7 and TLR9 directly  and administering 
ODNs to SLE prone mice significantly reduces the severity of the disease phenotype (Patole, 
et al., 2005). 
19 
Systemic sclerosis (SSc) is a complex autoimmune disease involving many systems with 
clinical presentation resulting from tissue fibrosis and extensive vasculopathy (Saigusaa, et al., 
2015).  IFN regulatory factor 5 (IRF5) is a potential disease susceptibility gene for SSc.  
Furthermore, IRF5 is activated by TLR4 and binds to promoters of various genes leading to 
SSc disease pathology (Saigusaa, et al., 2015).  Potential TLR4 endogenous ligands are up-
regulated in SSc, skin lesions (Bhattacharyya S, 2013., Bhattacharyya, et al., 2014., Takahashi 
T et al., 2015) and serum levels correlating with sever organ involvement and abnormal 
immunological activity (Yoshizaki A, et al., 2009., Yoshizaki A, et al., 2008).  HMGB1, 
hyaluronan and fibronectin extra domain are endogenous TLR4 ligands and these ligands are 
elevated in serum and dermis in SSc (Bhattacharyya S, 2013., Bhattacharyya, et al., 2014) 
(Yoshizaki A, et al., 2009., Yoshizaki A, et al., 2008).  TLR 4 signaling enhances TGF-β 
signaling and blocking TLR4 represses basal and TGF-β dependant fibroblast activation 
(Bhattacharyya S, 2013., Bhattacharyya, et al., 2014).  Moreover, in Tlr4-deficient mice 
bleomycin-induced dermal fibrosis is significantly decreased depite elevated levels of 
endogenous TLR4 ligands (Takahashi T et al., 2015).  In summary, pathogenesis of dermal 
fibrosis appears to involve TLR4 signalling and direct activation of dermal fibroblasts 
(Saigusaa, et al., 2015).   
Primary Sjögren’s syndrome (pSS) is a chronic, inflammatory autoimmune disease in which 
salivary and lacrimal glands are destroyed leading to drynesss of the mouth and eyes (Jonsson, 
et al., 2011).  TLR-family expression profiles differ greatly between pSS patients and healthy 
individuals (Zheng, Zhang, Yu, & Yang, 2010).  TLR1, TLR2 and TLR4 mRNAs are 
substantially overexpressed in pSS cultured salivary gland epithelial cells (SGECs) compared 
to controls (Zheng, Zhang, Yu, & Yang, 2010., Spachidou MP, et al., 2007).  As described 
earlier, peptidoglycan can activate TLR2 which in turn induces the production of IL-17 and IL-
23 in peripheral blood mononuclear cells (PBMCs) of pSS patients (Kwok S-K, et al., 2012).  
20 
As for the case of SLE and scleroderma, blockade of inflammatory cytokines and chemokines 
as well as TLRs by neutralizing antibodies or small molecule inhibitors may be potentially 
useful treatments for Sjögren’s syndrome (Kramer, 2014). 
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12. Conclusion 
   A growing body of evidence has shown that Toll-like receptors are impornatnt mediators of 
the immune response and immunity related diseases such as atherosclerosis or autoimmune 
disorders. Toll-like receptors, members of the larger Pattern-recognition recpetor family, 
recognize both exogenous and endogenous ligands to activate the immune system.  Ligand 
binding initiates a complex cascade of molecular events leading to activation of genes important 
for the immune response.  The amount of functional TLR seems to be related to the induction 
and maintenance of an autoimmune response. Chronic activation of the immune response leads 
to atherosclerosis or autoimmune disorders.  Evidence suggests that TLR 2 and TLR 4 are 
critical mediators involved in atherosclerosis, while the TLR 9 subset family is important in the 
pathogenesis of autoimmune disorders.  Preliminary evidence suggests that humanizied anti-
TLR2 antibodies and ODNs maybe therapeutically effective.  Future studies are now poised to 
expand the therapeutic potential of TLR inhibitors.   
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